logo-loader
viewApple Inc.

French antitrust authorities fine Apple $1.2B for anti-competitive behavior

The French Competition Authority, in its biggest-ever sanction, said the iPhone-maker was guilty of creating cartels within its distribution network

Apple Inc. - French antitrust authorities fine Apple $1.23B for anti-competitive behavior
Monday’s announcement is the second fine that French authorities have imposed on Apple in two months

French antitrust authorities on Monday fined Apple Inc (NASDAQ:AAPL) $1.2 billion for anti-competitive behavior.

The French Competition Authority, in its biggest-ever sanction, said the iPhone-maker was guilty of creating cartels within its distribution network and abusing the economic dependence of its outside resellers. 

“Apple and its two wholesalers agreed not to compete and prevent distributors from competing with each other, thereby sterilizing the wholesale market for Apple products,” said Isabelle de Silva, president of the French Competition Authority.

READ: Apple shares boosted by Chinese store announcement; Wedbush repeats 'Outperform'

A spokesperson for Apple told CNBC: “The French Competition Authority’s decision is disheartening. It relates to practices from over a decade ago and discards 30 years of legal precedent that all companies in France rely on with an order that will cause chaos for companies across all industries. We strongly disagree with them and plan to appeal.”

Monday’s announcement is the second fine that French authorities have imposed on Apple in two months. The regulators hit Apple with a $27.8 million fine in February over its software updates, which were concluded to have slowed down older iPhones.

Apple shares were down more than 7% to $$256.62 a share amid a broad-based move lower in stock markets. 

 

Quick facts: Apple Inc.

Price: 330.25 USD

NASDAQ:AAPL
Market: NASDAQ
Market Cap: $1.43 trillion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn continues to works on licensing deals as FDA continues its review on...

CytoDyn (OTCQB: CYDY) President and Chief Executive Officer Nader Pourhassan joined Steve Darling from Proactive to discuss a number of issues including the very latest on their clinical trials for a COVID-19 treatment. Pourhassan also told Proactive that they are in discussions with numerous...

4 hours, 13 minutes ago

2 min read